Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui
Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...
Stocktwits on MSN9h
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
Merck & Co., Inc. (MRK) said on Tuesday that it hasentered into an exclusive license agreement with China-based Jiangsu ...
Merck buys rights to heart disease drug in latest China deal
Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...
China.org.cn14h
China to improve quality, expand capacity of 'silver economy'
Photo/Xinhua] China will redouble its efforts to improve the quality and expand the capacity of its "silver economy," namely economic activities related to the country's large elderly population, Vice ...
Merck Bets $2B on China's Hengrui for Next Big Heart Drug
Big Pharma taps Chinese innovation again--this time for a potential blockbuster heart treatment targeting 1.4B people.
China Daily1d
Spring blooms paint China’s landscapes with striking colors
The Jiming Temple cherry blossoms have become one of the city’s signature attractions for spring tourism, as the quaint and ...
Apple executive eyes China's supply chains, expressing confidence in Chinese suppliers.
Apple's Chief Operating Officer Jeff Williams （right） visits a Chinese partner GoerTek on March 24, 2025, in Qingdao, East ...
PharmExec8h
Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug
Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...
China's ‘Netflix' iQiyi is set to open a theme park with virtual reality based on its own shows
Chinese videostreaming platform iQiyi plans to open its first theme park this year — the latest company to bet that local ...